Corrected QT (QTc) =<  msec\r\n* Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; If possible, alternative agents should be considered\r\n* Patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Correct QT interval (QTc) =<  msec; Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause torsades de pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Patients who are receiving drugs that prolong QTc are not eligible
Corrected QT (QTc) interval =<  milliseconds; Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Family history of long QT syndrome, with a QTc interval greater than (>)  millisecond (msec) at screening, or taking concurrent medications known to prolong QT/QTc interval
Current use of drugs that are known to prolong QT interval
Have used or plan to use from  days prior to enrollment through the end of the study medication known to lower the seizure threshold or prolong the QT interval
Current use of drugs that are known to prolong the QT interval
Every effort must be made to avoid the use of a concomitant medication that can prolong the corrected QT (QTc) interval while receiving selumetinib (hyd-sulfate AZD); if the patient cannot discontinue medications that prolong QTc interval while receiving selumetinib, close cardiac monitoring should be performed
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Uncorrectable electrolyte abnormalities, long QT syndrome or taking medications known to prolong the QT interval
Current treatment with medications that are well known to prolong the QT interval
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Subjects receiving concomitant medications that prolong corrected QT interval (QTc)
Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available
Required use of a concomitant medication that can prolong the QT interval
Treatment with medications that can prolong the QTc interval within the last  weeks
Use of drugs that could prolong the QT interval within  days before the start of study therapy.
Any medications that are known to prolong the QTc interval.
Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval
Use of a drug known to prolong the cardiac QT interval.
Patients taking medications that have the potential to prolong the QT interval
Planned concomitant use of medications known to prolong the QT/QTc interval
COHORT : TRIPLE NEGATIVE BREAST CANCER: Patients with a mean QTcF interval of >  msec or receiving therapeutic agents known to prolong the QT interval
COHORT : ENDOMETRIAL CANCER: Patients with a mean corrected QT (QTc) interval of >  msec or receiving therapeutic agents known to prolong the QT interval
Taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ? half-lives prior to dosing (If equivalent medication is not available QTc will be closely monitored)
Required use of a concomitant medication that can prolong the QT interval
Unable or unwilling to discontinue concomitant use of drugs that are known to prolong the QT interval.
Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within  half-lives or  days prior to starting study drug) or replaced by safe alternative medication.
Concurrent therapy with medications known to prolong the QT interval and/or associated with Torsade de Pointes arrhythmia
Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least five half-lives prior to treatment
Medications known to prolong corrected QT (QTC) are not allowed
Current or planned use of agents that prolong or suspected to prolong QTc
Patients must not be receiving other medications known to prolong the QT interval at the time of study entry or while on protocol therapy
Patients who are on treatment with drugs known to prolong the QT/QTc interval.
Patients who have a mean corrected QT (QTc) interval >  ms at base line will be excluded; concomitant use of agents that prolong the QT interval will be avoided
The use of concomitant medications that prolong the QT/QTc interval.
Patients receiving medications that have the potential to prolong the QT interval
Patients must not be planning to receive any concomitant medication known to prolong QT interval
Patients must not be taking within  days prior to sub-study registration, nor plan to take while on protocol treatment drugs that are known to prolong the QT interval
Patients who are receiving drugs that prolong the QTc are not eligible
Concomitant medication(s) known to increase the QT interval
Patients taking medications that are known to prolong the QT interval
Patient must not be taking drugs known to prolong the QTc interval; such drugs should be discontinued at least  half-lives prior to randomization
Patients who require use of a concomitant medication that can prolong the QT interval
Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval
Family history of long QT syndrome or other risk factors for torsades de pointes, and/or the use of concomitant medications that prolong the QT/QTc interval
Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within  half-lives or  days prior to starting study drug) or replaced by safe alternative medication
Current use of drugs that are known to prolong the QT interval
Patient requires the use of concomitant medications that are contraindicated with cardiac glycosides and/or are known to prolong the QT/QTc interval during study participation (see Appendix ).
Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g. within  half-lives or  days prior to starting study drug)
Other medications known to prolong QT interval should be discontinued and if not possible, patient is excluded from this study
Concurrent treatment with any agent known to prolong the corrected QT (QTc) interval
Subjects taking medications that are known to prolong the QT interval (see Section ..).
Current use of drugs that are known to prolong the QT interval
Current use of drugs known to prolong the QTc interval including class Ia and III antiarrhythmics or history of congenital long QTc syndrome
Planned concomitant use of medications known to prolong the QT/QTc interval
Subjects taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ? half-lives prior to dosing.
Use of medications that are known to prolong cause QT prolongation
Current use of drugs that are known to prolong the QT interval
the potential to prolong the QT interval, or
Patients who are taking medications that prolong QT interval and have a risk of Torsades de Pointes (Appendix F) or who have a history of long QT syndrome
Congenital long QT syndrome or subjects taking concomitant medications known to prolong the QT interval (e.g., tricyclics, azithromycin, methadone).
Subject is taking medication known to prolong the QT interval.
Participants with mean corrected QTc interval >  msec, as assessed within  weeks prior to enrollment, or participants who require medication known to prolong the QT interval
Caution should be used if patients are required to use a concomitant medication that can prolong the QT interval and efforts should be made to switch to a different medication before the patient begins treatment under an experimental arm
Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
Subjects taking medications that are known to prolong the QT interval
Patients taking medications known to prolong the QTc interval directly or that interact pharmacodynamically with medicines to prolong the QTc interval.
Must not have QT interval of > millisecond.
Ongoing treatment with any drugs known to prolong the QTc interval, including anti-arrhythmic medications (stable regimen of antidepressants of the selective serotonin reuptake inhibitor (SSRI) class is allowed))
Patients who are receiving drugs that prolong the QTc are not eligible
Use of a concomitant medication that can prolong the QT interval is strongly discouraged and patients should be advised to discontinue use of these medications during the study period and alternatives selected when indicated
Patients with a mean QTc interval greater than ms are excluded. Avoid concomitant administration of agents that prolong the QT interval, except at the discretion of the investigator. If advised, patients should discontinue the use of these agents at least  weeks before the study begins. No uncontrolled arrhythmias.
Patients may not be receiving any medications that are known to prolong QT interval unless reviewed and approved by the principal investigator (PI)
Risk factors for torsades de pointes such as:\r\n* Uncontrolled hypokalemia\r\n* Uncontrolled hypomagnesemia or hypermagnesemia\r\n* Cardiac failure (New York Heart Association class II or higher)\r\n* Clinically significant/symptomatic bradycardia (hear rate [HR] < ), or high-grade atrioventricular (AV) block\r\n* Known diagnosis of QT prolongation (QTc >= ) or family history of long QT syndrome\r\n* Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), human immunodeficiency virus [HIV], cirrhosis, uncontrolled hypothyroidism or cardiac failure\r\n* Concomitant medications known to prolong the QT interval during the same time as pasireotide is to be administered (unless approved by principal investigator [PI] and QTc < ; standard transplant medications that are known to prolong the QT (e.g. azoles, ondansetron, etc.) are permitted but caution is advised and patients should be closely monitored)
Current treatment with medications known to prolong the QT interval Stage I:
Patients on medications that prolong QT interval, per principal investigator (PI) discretion
Co-administration of drugs that prolong QT interval, cytochrome P, family , subfamily A, polypeptide  (CYPA) inducers, or other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber)
QTCF >  ms, inability to measure QT interval on ECG, personal or family history of long QT syndrome, requirement for medications that have the potential to prolong the QT interval
Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval
Participants taking any drug known to prolong QTc interval within at least  weeks before the start of the study drug and during the conduct of the study